VEGFA and endophthalmitis: In addition to the general complications of intravitreal drug delivery (endophthalmitis, retinal detachment, traumatic cataract, subconjunctival hemorrhage, uveitis, and pain), possible systemic complications of anti-VEGF agents have also been cited as a concern [17,18,19,20,21,22,23,24,25].